Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Rating of "Moderate Buy" by Analysts

Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are currently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $8.4444.

A number of equities research analysts have recently weighed in on the stock. Robert W. Baird cut their target price on shares of Allogene Therapeutics from $12.00 to $9.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 14th. JMP Securities reaffirmed a "market perform" rating on shares of Allogene Therapeutics in a research note on Monday, August 4th. Citizens Jmp lowered shares of Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Wednesday, May 14th. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Allogene Therapeutics in a research note on Monday, August 4th. Finally, Oppenheimer dropped their price objective on shares of Allogene Therapeutics from $10.00 to $9.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 14th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Caption Management LLC purchased a new position in shares of Allogene Therapeutics during the fourth quarter valued at approximately $32,000. Syon Capital LLC purchased a new position in shares of Allogene Therapeutics during the fourth quarter valued at approximately $39,000. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Allogene Therapeutics during the first quarter valued at approximately $28,000. KLP Kapitalforvaltning AS purchased a new position in shares of Allogene Therapeutics during the fourth quarter valued at approximately $43,000. Finally, Brooklyn Investment Group purchased a new position in shares of Allogene Therapeutics during the first quarter valued at approximately $45,000. 83.63% of the stock is owned by hedge funds and other institutional investors.

Allogene Therapeutics Trading Up 1.4%

Shares of ALLO stock traded up $0.02 during mid-day trading on Monday, reaching $1.06. The stock had a trading volume of 6,938,887 shares, compared to its average volume of 4,408,269. The stock's 50-day moving average price is $1.26 and its two-hundred day moving average price is $1.47. Allogene Therapeutics has a 52-week low of $0.86 and a 52-week high of $3.78. The firm has a market capitalization of $230.76 million, a PE ratio of -0.86 and a beta of 0.35.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.05. On average, equities research analysts forecast that Allogene Therapeutics will post -1.28 earnings per share for the current year.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).